Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ND-L02-s0201 in Idiopathic Pulmonary Fibrosis
jRCT2080225045Phase 2Completed
- Sponsor
- Nitto
- Start
- Feb 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ND-L02-s0201 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Nitto. Primary endpoints: Safety and tolerability of ND-L02-s0201, Biological activity of ND-L02-s0201 and 1 more. Started Feb 2020; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2080225045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225045.